文献速递心力衰竭与心肌病

射血分数降低心力衰竭住院期间启动SGLT2抑制剂

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本文论述射血分数降低心力衰竭患者住院期间启动钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)的合理性。SGLT2i临床获益在数天至数周内快速累积,安全耐受性好,对血压影响极小,不增加不良肾脏事件风险。延迟至门诊启动无获益证据,反而增加出院后早期临床恶化和死亡风险。

要点

  • SGLT2i获益在数天至数周内快速累积,适合住院期间启动。
  • 延迟至门诊启动增加出院后早期恶化和死亡风险,无获益证据。
  • 因心衰住院患者30天内死亡或再入院风险高,应住院期间尽早启动。

核心结论

  • 心衰住院期间是启动SGLT2i的最佳时机,延迟启动无获益且增加出院后早期临床恶化和死亡风险。

主要发现

  • SGLT2i临床获益在数天至数周内快速累积,安全耐受性好,对血压影响极小,不增加不良肾脏事件风险。
  • 延迟至门诊启动无获益证据,反而使患者暴露于出院后早期临床恶化和死亡的超额风险。
  • 其他指南推荐的心衰药物延迟至美国门诊启动时,超过75%在接下来一年内不会启动。
  • 因心衰恶化住院的患者中,1/4在30天内死亡或再入院。

临床怎么用

  • 将心衰住院期视为启动SGLT2i的最佳时机,以应有紧迫性治疗该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rao, Murray, Butler, et al. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2021. PMID: 34763778. doi:10.1016/j.jacc.2021.08.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。